Abstract:Background: Clostridioides difficile ( C . difficile ) is a spore-forming bacterial species that ubiquitously exists in the environment. Colonization by C. difficile is highly prevalent in infants, while fewer than 5% of adults are asymptomatic carriers. Disruption of the microbiome, such as through antibiotic treatment, triggers the germination of bacterial spores into numerous vegetative cells. These cells then produce enterotoxins that result in watery diarrhea and colonic inflammation. If left untreated, C. difficile infection (CDI) can lead to pseudomembranous colitis with the potentially life-threatening complication of toxic megacolon. Summary: Over the past few decades, the incidence, morbidity, and mortality associated with CDIs have increased. They have emerged as the primary cause of nosocomial gastrointestinal infections in industrialized countries, posing a significant burden on healthcare systems. Despite antibiotics often being the cause of CDIs, they remain the standard treatment. However, a considerable number of patients treated with antibiotics will experience recurrent CDI (rCDI). Microbiota-based therapies targeting the core issue of CDI – antibiotic-induced dysbiosis – hold promise for rCDI treatment. While data for probiotics are insufficient, numerous studies have highlighted the effectiveness of fecal microbiota transplantation (FMT) as a safe and viable therapeutic option for rCDI. This approach is now endorsed by multiple guidelines. Nonetheless, regulatory prerequisites, such as comprehensive stool donor screening, restrict the widespread adoption of FMT beyond specialized centers. Recently, the US Food and Drug Administration has approved two commercial microbiota-based therapeutics to prevent CDI recurrence. These therapeutics are available by prescription in the USA. RBX2660 (REBYOTATM) comprises a diverse consortium of live microbes derived from human stool and is administered via enema. On the other hand, SER-109 (VOWSTTM) is an orally administered spore-based medication. In this review, we discuss the potential of microbiota-based treatments for rCDI against the background of medico-legal challenges associated with classical FMT. Key Messages: FMT has emerged as a highly effective cure for rCDI. Nonetheless, regulatory prerequisites and laborious preparation procedures impede its widespread use. The establishment of ready-to-use microbiota-based therapeutics in clinical practice is necessary. In the USA, the recent approval of the first two commercial medications, including a spore-based oral preparation, marks a significant step forward.

Metabolite distribution in cells.

Gut Microbiota–Gut Metabolites and Clostridioides difficile Infection: Approaching Sustainable Solutions for Therapy

Ultrashort-lived radioisotopes for visualizing blood vessels and organs.

Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections

Probiotics: insights and new opportunities for Clostridioides difficile intervention

Advances in Therapeutic Strategies for the Management of Clostridioides difficile Infection

Identification of Antimicrobial Resistance Genes and Drug Targets in Antibiotic-Resistant Clostridioides difficile Clinical Isolates

Microbial ecology between Clostridioides difficile and gut microbiota

Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile

Modulation of Lactobacillus Rhamnosus GG on the Gut Microbiota and Metabolism in Mice with Clostridioides Difficile Infection

Making Teamwork Work: Team Knowledge for Team Effectiveness

New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation

[Root length of upper canines and orthodontic therapy].

The microbial metabolite urolithin A reduces Clostridioides difficile toxin expression and toxin-induced epithelial damage

Evaluating the antibacterial, antibiofilm, and anti-toxigenic effects of postbiotics from lactic acid bacteria on Clostridium difficile

<i>Akkermansia muciniphila</i> Ameliorates <i>Clostridioides difficile</i> Infection in Mice by Modulating the Intestinal Microbiome and Metabolites

The Evaluation of Fecal Microbiota Transplantation Vs Vancomycin in a Clostridioides Difficile Infection Model.

Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection

Core-genome-mediated promising alternative drug and multi-epitope vaccine targets prioritization against infectious Clostridium difficile

Compelling Evidence that Exposure Therapy for PTSD Normalizes Brain Function.

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies